| FDA Sends Letter to AMAG Pharmaceuticals Over Feraheme - PharmaLive.com (press release) |
|
|
PharmaLive.com (press release) The Nephrology direct mailer is misleading because it overstates the efficacy of Feraheme. Thus, the Nephrology direct mailer misbrands the drug in violation of the Federal Food, Drug, and Cosmetic Act (the Act), 21 USC 352(a) and FDA's implementing |